BIOAGE LABS INC (BIOA) Forecast, Price Target & Analyst Ratings
NASDAQ:BIOA • US09077V1008
21.07 USD
+0.61 (+2.98%)
At close: Mar 4, 2026
21.07 USD
0 (0%)
After Hours: 3/4/2026, 6:09:51 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOAGE LABS INC (BIOA).
Forecast Snapshot
Consensus Price Target
$30.60
+ 45.23% Upside
Next Earnings Forecast
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$0.77
Revenue Estimate1.163M
ChartMill Buy Consensus
78.18%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$30.60
Upside
+ 45.23%
From current price of $21.07 to mean target of $30.60, Based on 11 analyst forecasts
Low
$9.09
Median
$19.38
High
$76.65
Price Target Revisions
1 Month
150.00%
3 Months
210.34%
Price Target Summary
11 analysts have analysed BIOA and the average price target is 30.6 USD. This implies a price increase of 45.23% is expected in the next year compared to the current price of 21.07.
The average price target has been revised upward by 210.34% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.18%
BIOA was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about BIOA.
In the previous month the buy percentage consensus was at a similar level.
BIOA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Oppenheimer | Initiate | Outperform |
| 2026-02-18 | Jefferies | Upgrade | Hold -> Buy |
| 2026-01-27 | Piper Sandler | Initiate | Overweight |
| 2025-12-08 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2025-10-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-22 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-03-24 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-02-28 | William Blair | Initiate | Market Perform |
| 2024-12-09 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-12-09 | Jefferies | Downgrade | Buy -> Hold |
| 2024-10-21 | Morgan Stanley | Initiate | Overweight |
| 2024-10-21 | Citigroup | Initiate | Buy |
| 2024-10-21 | Jefferies | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$0.77
Revenue Estimate1.163M
Revenue Q2QN/A
EPS Q2Q60.80%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
-20.01%
Revenue (3 Months)
-20.01%
EPS (1 Month)
1.73%
EPS (3 Months)
2.00%
Next Earnings Summary
BIOA is expected to report earnings on 3/19/2026. The consensus EPS estimate for the next earnings is -0.77 USD and the consensus revenue estimate is 1.16M USD.
The next earnings revenue estimate has been revised downward by 20.01% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -58.12% | N/A -73.34% | N/A -100.00% | N/A | N/A | N/A | N/A | N/A 121.74% | ||||
| EBITDA YoY % growth | -39.84M | -48.238M -21.08% | -78.027M -61.75% | N/A -15.77% | N/A -25.88% | N/A 6.18% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -39.969M | -48.4M -21.09% | -78.194M -61.56% | N/A -16.63% | N/A 63.60% | N/A -32.46% | N/A -257.93% | N/A -30.43% | N/A -22.07% | N/A -17.77% | N/A -14.18% | N/A 68.49% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A 71.53% | N/A -26.47% | N/A -3.74% | N/A | N/A | N/A -20.26% | N/A -12.58% | N/A -13.45% | N/A 60.77% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.77 60.80% | -0.69 -90.64% | -0.71 -17.64% | -0.72 -28.90% | -0.73 4.91% | -0.72 -5.52% | -0.74 -5.49% | -0.79 -8.81% | -0.81 -9.72% | -0.72 | -0.74 | -0.79 |
| Revenue Q2Q % growth | 1.163M | 918K -36.73% | 1.836M -23.88% | 1.836M -10.61% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -24.173M 4.05% | -23.471M -43.04% | -25.7M -4.15% | -26.618M -15.75% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -25.538M -0.69% | -25.603M -55.68% | -25.716M -3.82% | -26.634M -15.10% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.60%
EPS Next 5 Year
8.69%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-10.64%
EBIT Next 5 Year
N/A
BIOAGE LABS INC / BIOA Forecast FAQ
What is the average price target for BIOAGE LABS INC (BIOA) stock?
11 analysts have analysed BIOA and the average price target is 30.6 USD. This implies a price increase of 45.23% is expected in the next year compared to the current price of 21.07.
Can you provide the upcoming earnings date for BIOAGE LABS INC?
BIOAGE LABS INC (BIOA) will report earnings on 2026-03-19.
Can you provide the consensus estimates for BIOAGE LABS INC next earnings?
The consensus EPS estimate for the next earnings of BIOAGE LABS INC (BIOA) is -0.77 USD and the consensus revenue estimate is 1.16M USD.
What is the number of analysts for BIOA stock?
The number of analysts covering BIOAGE LABS INC (BIOA) is 11.